{"id":60437,"date":"2024-02-28T06:48:51","date_gmt":"2024-02-28T06:48:51","guid":{"rendered":"https:\/\/medsname.com\/rioci-1\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rioci-1","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/rioci-1\/","title":{"rendered":"Rioci 1"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Rioci 1?<\/h3>\n<p style=\"margin:0;\"><strong>Rioci 1<\/strong> sunt comprimate de riociguat 1 mg de la un produc\u0103tor certificat WHO-GMP \u2014 un stimulator solubil al guanilat ciclazei (sGC) pentru <strong>hipertensiunea arterial\u0103 pulmonar\u0103 (HAP)<\/strong>. HAP este o boal\u0103 specific\u0103, progresiv\u0103 \u0219i rar\u0103 \u2014 <strong>nu este aceea\u0219i cu hipertensiunea sistemic\u0103<\/strong>. Cre\u0219te presiunea \u00een arterele pulmonare, nu \u00een arterele sistemice, \u0219i necesit\u0103 terapie specializat\u0103 dirijat\u0103 de un specialist \u00eentr-un centru acreditat pentru HAP. Riociguat a fost introdus de Bayer \u00een 2013 sub denumirea <strong>Adempas<\/strong> \u2014 primul stimulator de sGC aprobat pentru uz uman. Aprobat de FDA pentru dou\u0103 forme specifice de hipertensiune pulmonar\u0103: hipertensiunea arterial\u0103 pulmonar\u0103 (HAP, Grupa 1 WHO) \u0219i hipertensiunea pulmonar\u0103 tromboembolic\u0103 cronic\u0103 (HTEPC, Grupa 4 WHO) \u2014 singurul medicament oral aprobat pentru HTEPC inoperabil. Activeaz\u0103 direct guanilat ciclaza solubil\u0103 (receptorul NO) \u00een mu\u0219chiul neted arterial pulmonar, cresc\u00e2nd cGMP \u0219i produc\u00e2nd vasodilata\u021bie pulmonar\u0103. Spre deosebire de inhibitorii PDE5, riociguat stimuleaz\u0103 sGC chiar \u0219i \u00een absen\u021ba NO, oferind activitate \u00een paturile vasculare deficiente \u00een NO, caracteristice HAP \u0219i HTEPC. Dozare: \u00cencepe\u021bi cu 1 mg de trei ori pe zi (la intervale de 8 ore); titra\u021bi la fiecare 2 s\u0103pt\u0103m\u00e2ni cu cre\u0219teri de 0,5 mg \u00een func\u021bie de tensiunea arterial\u0103 sistolic\u0103 (trebuie s\u0103 r\u0103m\u00e2n\u0103 &gt;95 mmHg) \u0219i simptome. Doza \u021bint\u0103 este de 2,5 mg de trei ori pe zi. Tratamentul HAP este de obicei o terapie combinat\u0103 ini\u021biat\u0103 \u0219i monitorizat\u0103 \u00eentr-un centru specializat; aceasta nu este o boal\u0103 pentru auto-tratament.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">Ce este Rioci 1?<\/h2>\n<p>Rioci 1 sunt comprimate de 1 mg riociguat de la un produc\u0103tor certificat WHO-GMP, furnizate \u00een cutii de 10-180 comprimate. Riociguat a fost introdus de Bayer \u00een 2013 sub denumirea <strong>Adempas<\/strong> \u2014 primul stimulator de sGC aprobat pentru uz uman. Aprobat de FDA pentru dou\u0103 forme specifice de hipertensiune pulmonar\u0103: hipertensiunea arterial\u0103 pulmonar\u0103 (HAP, Grupa 1 WHO) \u0219i hipertensiunea pulmonar\u0103 tromboembolic\u0103 cronic\u0103 (HTEPC, Grupa 4 WHO) \u2014 singurul medicament oral aprobat pentru HTEPC inoperabil.<\/p>\n<p><strong>Hipertensiunea arterial\u0103 pulmonar\u0103 (HAP) nu este hipertensiune sistemic\u0103.<\/strong> HAP se refer\u0103 \u00een mod specific la cre\u0219terea presiunii \u00een circula\u021bia arterial\u0103 pulmonar\u0103 (\u226520 mmHg presiune arterial\u0103 pulmonar\u0103 medie cu rezisten\u021b\u0103 vascular\u0103 pulmonar\u0103 \u22652 unit\u0103\u021bi Wood conform ghidurilor ESC\/ERS 2022). Este rar\u0103 (estimat\u0103 la 15-50 la un milion de adul\u021bi), progresiv\u0103 \u0219i, f\u0103r\u0103 tratament, are un prognostic slab (supravie\u021buire istoric\u0103 la 5 ani \u223c30%). Terapia modern\u0103 direc\u021bionat\u0103 c\u0103tre HAP a \u00eembun\u0103t\u0103\u021bit supravie\u021buirea la 5 ani la 60-70% \u00een centrele de specialitate.<\/p>\n<p>Candida\u021bii pentru Rioci 1 au fost diagnostica\u021bi \u00eentr-un centru specializat pentru HAP prin cateterism cardiac drept, cu simptome func\u021bionale WHO\/NYHA clase II-IV \u0219i HAP confirmat\u0103 (Grupul 1 WHO) sau \u2014 pentru riociguat \u2014 HTEPC inoperabil\u0103 sau persistent\u0103 (Grupul 4 WHO). Acesta nu este un medicament pentru hipertensiunea obi\u0219nuit\u0103 sau pentru terapie auto-ini\u021biat\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Riociguat<\/h2>\n<p>Activeaz\u0103 direct guanilat ciclaza solubil\u0103 (receptorul NO) \u00een mu\u0219chiul neted arterial pulmonar, cresc\u00e2nd cGMP \u0219i produc\u00e2nd vasodilata\u021bie pulmonar\u0103. Spre deosebire de inhibitorii PDE5, riociguat stimuleaz\u0103 sGC chiar \u0219i \u00een absen\u021ba NO, oferind activitate \u00een paturile vasculare deficiente \u00een NO, caracteristice HAP \u0219i HTEPC.<\/p>\n<h2 class=\"wp-block-heading\">Dovezi<\/h2>\n<p><strong>PATENT-1 (2013)<\/strong> \u2014 riociguat la 443 de pacien\u021bi cu HAP; distan\u021ba de mers pe jos \u00een 6 minute a \u00eembun\u0103t\u0103\u021bit cu 30 m fa\u021b\u0103 de placebo, cu o clas\u0103 func\u021bional\u0103 WHO mai bun\u0103 \u0219i o \u00eenr\u0103ut\u0103\u021bire clinic\u0103 \u00eent\u00e2rziat\u0103. <strong>CHEST-1 (2013)<\/strong> \u2014 riociguat la 261 de pacien\u021bi cu HTEPC inoperabil\u0103 sau persistent\u0103; mersul pe jos \u00een 6 minute a \u00eembun\u0103t\u0103\u021bit cu 46 m fa\u021b\u0103 de placebo.<\/p>\n<h2 class=\"wp-block-heading\">Doza \u0219i Monitorizare<\/h2>\n<p><strong>Doza:<\/strong> \u00cencepe\u021bi cu 1 mg de trei ori pe zi (la intervale de 8 ore); titra\u021bi la fiecare 2 s\u0103pt\u0103m\u00e2ni cu cre\u0219teri de 0,5 mg \u00een func\u021bie de tensiunea arterial\u0103 sistolic\u0103 (trebuie s\u0103 r\u0103m\u00e2n\u0103 &gt;95 mmHg) \u0219i simptome. Doza \u021bint\u0103 este de 2,5 mg de trei ori pe zi.<\/p>\n<p><strong>Monitorizare:<\/strong> la evaluarea ini\u021bial\u0103 \u0219i apoi la fiecare 3-6 luni \u2014 clas\u0103 func\u021bional\u0103 WHO, distan\u021ba parcurs\u0103 \u00een 6 minute, NT-proBNP, ecocardiografie repetat\u0103 \u0219i (la intervale mai mari) cateterism cardiac drept. Toate efectuate printr-un centru specializat \u00een HAP.<\/p>\n<p><strong>Monitorizarea TA:<\/strong> tensiunea arterial\u0103 sistolic\u0103 trebuie s\u0103 r\u0103m\u00e2n\u0103 &gt;95 mmHg; titrarea este \u00eentrerupt\u0103 sau inversat\u0103 \u00een caz de hipotensiune simptomatic\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<ul>\n<li><strong>Hipotensiune<\/strong> \u2014 limitare de doz\u0103; titra\u021bi lent.<\/li>\n<li><strong>Hemoptizie<\/strong> \u2014 risc crescut, \u00een special \u00een CTEPH.<\/li>\n<li>Sincop\u0103<\/li>\n<li>Dureri de cap, ame\u021beli<\/li>\n<li>Edem periferic<\/li>\n<li>Anemie<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Contraindica\u021bii<\/h2>\n<ul>\n<li><strong>Inhibitori PDE5 concomitenten\u021bi<\/strong> (Sildenafil, Tadalafil) \u2014 cre\u0219tere aditiv\u0103 de cGMP, hipotensiune sever\u0103. Combina\u021bie contraindecat\u0103.<\/li>\n<li><strong>Nitra\u021bi sau donatori de NO concomitenten\u021bi<\/strong> \u2014 acela\u0219i motiv; contraindecat.<\/li>\n<li>Sarcin\u0103 \u2014 toxicitate embrionar\u0103 (program REMS \u00een SUA: femeile trebuie s\u0103 foloseasc\u0103 contracep\u021bie, test de sarcin\u0103 lunar).<\/li>\n<\/ul>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Este hipertensiunea arterial\u0103 pulmonar\u0103 acela\u0219i lucru cu \u201chipertensiunea arterial\u0103\u201d?<\/h3>\n<p>Nu. Hipertensiunea sistemic\u0103 este presiune crescut\u0103 \u00een circula\u021bia general\u0103 \u0219i este foarte frecvent\u0103; HAP este presiune crescut\u0103 specific \u00een circula\u021bia pulmonar\u0103 \u0219i este rar\u0103. Au cauze diferite, speciali\u0219ti diferi\u021bi (\u00eengrijirea HAP este de obicei asigurat\u0103 de echipe de pneumologie\/cardiologie \u00een centre ter\u021biare) \u0219i tratamente medicamentoase foarte diferite. Un medicament care scade tensiunea arterial\u0103 sistemic\u0103 (ACEi, ARB, CCB, tiazid\u0103) are de obicei un efect mic asupra HAP.<\/p>\n<h3 class=\"wp-block-heading\">De ce necesit\u0103 Rioci 1 monitorizare specializat\u0103?<\/h3>\n<p>HAP este o boal\u0103 gestionat\u0103 de speciali\u0219ti, cu un model de supraveghere bazat pe registre \u00een majoritatea \u021b\u0103rilor. Medicamentele sunt scumpe, au efecte adverse specifice (\u00een special hepatotoxicitate pentru ERA \u0219i hipotensiune pentru stimulatorii sGC), iar titrarea dozei depinde de evalu\u0103ri seriate (testul de 6 minute, clasa func\u021bional\u0103, NT-proBNP, ecocardiografie). Autogestionarea off-label prezint\u0103 riscuri mari de deteriorare clinic\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua Rioci 1 \u00eempreun\u0103 cu medicamente pentru disfunc\u021bie erectil\u0103?<\/h3>\n<p><strong>Nu \u2014 absolut contraindicated.<\/strong> Inhibitorii PDE5 (sildenafil, tadalafil, vardenafil) combina\u021bi cu riociguat provoac\u0103 hipotensiune sever\u0103 aditiv\u0103. Dac\u0103 ave\u021bi nevoie de terapie pentru DE, discuta\u021bi alternative cu echipa dumneavoastr\u0103 de HAP; unele regimuri de HAP utilizeaz\u0103 inhibitori PDE5 \u00een loc de riociguat ca vasodilatator pulmonar.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua Rioci 1 \u00een timpul sarcinii?<\/h3>\n<p><strong>Nu.<\/strong> Toxicitate embrionar\u0103 documentat\u0103 \u00een studii pe animale; sunt necesare teste de sarcin\u0103 \u0219i contracep\u021bie.<\/p>\n<h3 class=\"wp-block-heading\">Unde pot cump\u0103ra Rioci 1 online?<\/h3>\n<p>Pute\u021bi cump\u0103ra Rioci 1 (riociguat 1 mg, 10-180 comprimate) de la MedsBase cu ambalaj discret \u0219i livrare la nivel mondial.<\/p>\n<h2 class=\"wp-block-heading\">Medicamente cardio-vasculare conexe<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cardace\/\">Cardace \u2014 Ramipril (inhibitor ACE)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ecopril\/\">Ecopril \u2014 Clopidogrel 75 mg (antiagregant plachetar)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ecosprin\/\">Ecosprin \u2014 Aspirin\u0103 75\/150 mg (antiagregant plachetar)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lonitab\/\">Lonitab \u2014 Minoxidil 5 mg (vasodilatator oral)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/waf-5\/\">Waf-5 \u2014 Warfarin 5 mg (VKA)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xarelto-20\/\">Xarelto 20 \u2014 Rivaroxaban 20 mg (DOAC)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/high-blood-pressure-medication\/\"><strong>R\u0103sfoi\u021bi toate medicamentele pentru hipertensiune arterial\u0103<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Dezaprobare medical\u0103.<\/strong> Aceast\u0103 pagin\u0103 are scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical al unui medic calificat. Hipertensiunea, insuficien\u021ba cardiac\u0103 \u0219i aritmiile necesit\u0103 diagnostic, monitorizare \u0219i individualizarea dozei de c\u0103tre un medic \u2014 utiliza\u021bi \u00eentotdeauna beta-blocante sub \u00eendrumare medical\u0103.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/seretra\/\">Seretra<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/proclid-5\/\">Proclid 5<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tacroz-forte-ointment\/\">Unguent Tacroz Forte<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/syndopa\/\">Syndopa<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/caditam\/\">Caditam<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Rioci 1 sunt comprimate de riociguat 1 mg \u2014 primul stimulator solubil al guanilat ciclazei (sGC), ini\u021bial Bayer Adempas (2013). Aprobat pentru hipertensiunea arterial\u0103 pulmonar\u0103 (PAH, Grupa 1 WHO) \u0219i singurul medicament oral pentru hipertensiunea pulmonar\u0103 tromboembolic\u0103 cronic\u0103 inoperabil\u0103 (CTEPH, Grupa 4 WHO). Dovezile din studiile PATENT-1 \u0219i CHEST-1. Boal\u0103 gestionat\u0103 de speciali\u0219ti \u2014 nu hipertensiune obi\u0219nuit\u0103. Contraindicat cu inhibitorii PDE5 \u0219i nitra\u021bi.<\/p>","protected":false},"featured_media":60438,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[4861,4862],"class_list":{"0":"post-60437","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-rioci","11":"product_tag-riociguat","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/60437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=60437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/60438"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=60437"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=60437"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=60437"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=60437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}